Compare DK & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | LGND |
|---|---|---|
| Founded | 2001 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 2017 | 1997 |
| Metric | DK | LGND |
|---|---|---|
| Price | $74.25 | $302.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $76.77 | ★ $344.25 |
| AVG Volume (30 Days) | ★ 2.0M | 210.4K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | 95.67 | ★ 2886.36 |
| EPS | N/A | ★ 1.63 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | $33.50 | $8.04 |
| Revenue Next Year | N/A | $31.71 |
| P/E Ratio | ★ N/A | $180.98 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $25.85 | $175.89 |
| 52 Week High | $82.27 | $326.63 |
| Indicator | DK | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 56.38 |
| Support Level | $61.60 | $276.71 |
| Resistance Level | $77.40 | $320.45 |
| Average True Range (ATR) | 3.37 | 10.72 |
| MACD | 0.12 | -0.43 |
| Stochastic Oscillator | 74.61 | 63.07 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.